$OTLC
Oncotelic Therapeutics, Inc. Stock $otlc

$otlc Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000149315223012352 Filed on April 14, 2023

Income Statement

Concept	2023 Q2	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$238.8K	$348.4K	$4.854M
YoY Change	61.75%	-64.86%	-11.22%
% of Gross Profit
Research & Development		$66.21K	$756.9K
YoY Change		-87.35%	-79.31%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
% of Gross Profit
Operating Expenses	$6.322M	$414.6K	$9.722M
YoY Change	2366.46%	-72.63%	6.53%
Operating Profit	-$6.322M		-$9.722M
YoY Change	2366.46%		6.53%
Interest Expense	$257.4K	-$867.5K	$2.971M
YoY Change	-76.49%	57.81%	-273.68%
% of Operating Profit
Other Income/Expense, Net	-$528.1K	$48.83K	$14.40M
YoY Change	-103.25%		-1134.8%
Pretax Income	-$6.850M	-$5.344M	$4.677M
YoY Change	-142.89%	171.13%	-144.47%
Income Tax
% Of Pretax Income
Net Earnings	-$6.757M	-$5.289M	$5.095M
YoY Change	-142.2%	194.81%	-154.25%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.02		$0.01
Diluted Earnings Per Share	-$0.02	-$0.01	$0.01
COMMON SHARES
Basic Shares Outstanding	392.9M shares	391.1M shares	384.1M shares
Diluted Shares Outstanding			457.3M shares

Balance Sheet

Concept	2023 Q2	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$181.9K	$241.5K	$241.5K
YoY Change	-54.51%	-57.55%	-57.55%
Cash & Equivalents	$201.9K	$241.5K	$241.5K
Short-Term Investments
Other Short-Term Assets	$80.74K	$41.96K	$41.96K
YoY Change	84.72%	8.2%	8.2%
Inventory
Prepaid Expenses
Receivables	$18.98K	$19.75K	$19.75K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$281.6K	$303.2K	$303.2K
YoY Change	-39.21%	-51.67%	-51.67%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill	$5.988M	$12.07M
YoY Change	-63.0%	-42.69%
Intangibles
YoY Change
Long-Term Investments	$22.64M	$22.64M	$22.64M
YoY Change	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$29.73M	$35.81M	$35.81M
YoY Change	-25.53%	55.81%	55.81%
TOTAL ASSETS
Total Short-Term Assets	$281.6K	$303.2K	$303.2K
Total Long-Term Assets	$29.73M	$35.81M	$35.81M
Total Assets	$30.01M	$36.12M	$36.12M
YoY Change	-25.69%	52.95%	52.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.026M	$1.736M	$2.068M
YoY Change	8.29%	-9.96%	-11.28%
Accrued Expenses	$775.7K	$775.1K	$775.1K
YoY Change	-26.98%	-33.47%	-33.47%
Deferred Revenue
YoY Change
Short-Term Debt	$1.080M	$390.1K	$11.26M
YoY Change	302.75%	8.57%	128.63%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$18.09M	$16.92M	$16.92M
YoY Change	12.28%	9.5%	9.5%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.09M	$16.92M	$16.92M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$17.70M	$16.71M	$16.71M
YoY Change	10.41%	6.71%	6.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$32.90M	-$25.93M
YoY Change	65.33%	-16.42%
Common Stock	$3.975M	$3.918M
YoY Change	2.98%	4.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$12.32M	$19.41M	$19.41M
YoY Change
Total Liabilities & Shareholders Equity	$30.01M	$36.12M	$36.12M
YoY Change	-25.69%	52.95%	52.95%

Cashflow Statement

Concept	2023 Q2	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$6.757M	-$5.289M	$5.095M
YoY Change	-142.2%	194.81%	-154.25%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Cash From Operating Activities	-$448.6K	-$80.68K	-$1.500M
YoY Change	120.82%	-92.44%	-66.17%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$158.8K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	440.0K	68.25K	$1.125M
YoY Change	-12.87%	-95.62%	-75.16%
NET CHANGE
Cash From Operating Activities	-448.6K	-80.68K	-$1.500M
Cash From Investing Activities
Cash From Financing Activities	440.0K	68.25K	$1.125M
Net Change In Cash	-8.560K	-12.43K	-$327.3K
YoY Change	-102.84%	-102.53%	-445.45%
FREE CASH FLOW
Cash From Operating Activities	-$448.6K	-$80.68K	-$1.500M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	OTLC	Goodwill Derecognition Upon Recording Of Gain On Nonfinancial Asset GoodwillDerecognitionUponRecordingOfGainOnNonfinancialAsset		usd
CY2021	OTLC	Contribution From Shareholder For Payment Of Liabilities ContributionFromShareholderForPaymentOfLiabilities		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	OTLC	Common Shares Issued In Lieu Of Restricted Stock Units CommonSharesIssuedInLieuOfRestrictedStockUnits		usd
CY2022	OTLC	Paycheck Protection Program Loan Forgiven PaycheckProtectionProgramLoanForgiven		usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain EquitySecuritiesFvNiUnrealizedGain		usd
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Loss EquitySecuritiesFvNiUnrealizedLoss		usd
CY2021Q4	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent		usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss		usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Purchases FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPurchases		usd
CY2021	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Purchases FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPurchases		usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet		usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000908259
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2021Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022	OTLC	Ppp Loan Forgiveness PppLoanForgiveness		usd
CY2021	OTLC	Gain On Sale Of Nonfinancial Asset GainOnSaleOfNonfinancialAsset		usd
CY2021	OTLC	Reimbursement For Expenses Related Party ReimbursementForExpensesRelatedParty		usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2021	OTLC	Stock Issued During Period Value Conversion Of Preferred Stock StockIssuedDuringPeriodValueConversionOfPreferredStock		usd
CY2021	OTLC	Gain On Sale Of Nonfinancial Asset GainOnSaleOfNonfinancialAsset		usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022	OTLC	Research Development Expenses Paid By Debt ResearchDevelopmentExpensesPaidByDebt		usd
CY2022	OTLC	Common Shares Issued Issued In Lieu Of Restricted Stock Units CommonSharesIssuedIssuedInLieuOfRestrictedStockUnits		usd
CY2022	OTLC	Common Shares Issued In Lieu Of Services CommonSharesIssuedInLieuOfServices		usd
CY2022	OTLC	Paycheck Protection Program Loan Forgiveness PaycheckProtectionProgramLoanForgiveness		usd
CY2022	us-gaap	Depreciation Depreciation		usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022	OTLC	Repayments Of Convertible Notes Payable RepaymentsOfConvertibleNotesPayable		usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022	OTLC	Proceeds From Convertible Debt For Joint Venture ProceedsFromConvertibleDebtForJointVenture		usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2022	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt		usd
CY2022	OTLC	Proceeds From Payroll Protection Plan ProceedsFromPayrollProtectionPlan		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	0-21990
CY2022	dei	Entity Registrant Name EntityRegistrantName	Oncotelic Therapeutics, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-3679168
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	29397 Agoura Road
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 107
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Agoura Hills
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91301
CY2022	dei	City Area Code CityAreaCode	(650)
CY2022	dei	Local Phone Number LocalPhoneNumber	635-7000
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	29589799	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	392871880	shares
CY2022	dei	Auditor Firm AuditorFirmId	468
CY2022	dei	Auditor Name AuditorName	Rose, Snyder & Jacobs LLP
CY2022	dei	Auditor Location AuditorLocation	Encino, CA
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	241452	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	568769	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	20000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	20000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19748	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19748	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	21964	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	18778	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	303164	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	627295	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	201180	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	188339	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	821841	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1101760	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1101760	usd
CY2022Q4	us-gaap	Goodwill Goodwill	12071376	usd
CY2021Q4	us-gaap	Goodwill Goodwill	21062455	usd
CY2022Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	22640519	usd
CY2022Q4	us-gaap	Assets Assets	36116819	usd
CY2021Q4	us-gaap	Assets Assets	23613351	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2510864	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3092723	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	332432	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	403423	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	2625000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	2625000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	198140	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	340290	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	10091923	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	8166622	usd
CY2022Q4	OTLC	Convertible Debt And Short Term Debt Related Party Current ConvertibleDebtAndShortTermDebtRelatedPartyCurrent	1165048	usd
CY2021Q4	OTLC	Convertible Debt And Short Term Debt Related Party Current ConvertibleDebtAndShortTermDebtRelatedPartyCurrent	826862	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16923407	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15454920	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	278188	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	278188	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	391846880	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	391846880	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	375288146	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	375288146	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3918469	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3752881	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	41416632	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	35223842	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25926069	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31021050	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	19409032	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	7955673	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-215620	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	202758	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19193412	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8158431	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36116819	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23613351	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	756910	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3658617	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4853664	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5467266	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4111079	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	9721653	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	9125883	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-9721653	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-9125883	usd
CY2022	us-gaap	Interest Expense InterestExpense	2971046	usd
CY2021	us-gaap	Interest Expense InterestExpense	2002813	usd
CY2021	OTLC	Ppp Loan Forgiveness PppLoanForgiveness	346761	usd
CY2022	OTLC	Gain On Sale Of Nonfinancial Asset GainOnSaleOfNonfinancialAsset	16951477	usd
CY2022	OTLC	Reimbursement For Expenses Related Party ReimbursementForExpensesRelatedParty	-533485	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	142150	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	292149	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-257810	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-27504	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14398256	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1391407	usd
CY2022	us-gaap	Profit Loss ProfitLoss	4676603	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-10517290	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-418378	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1126248	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	5094981	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9391042	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	384075369	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	303078548	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	457299890	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	303078548	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8158431	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	158820	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	902141	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2905316	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	570717	usd
CY2022	OTLC	Adjustments To Additional Paid In Capital Warrant Issuedin Connection With Debt Issuance AdjustmentsToAdditionalPaidInCapitalWarrantIssuedinConnectionWithDebtIssuance	368375	usd
CY2022	OTLC	Adjustment Of Additional Paid In Capital Contribution From Shareholder For Payment Of Liabilities AdjustmentOfAdditionalPaidInCapitalContributionFromShareholderForPaymentOfLiabilities	828258	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	624751	usd
CY2022	us-gaap	Profit Loss ProfitLoss	4676603	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19193412	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	12480833	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	12480833	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	210301	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	226432	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	193641	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	420302	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	969754	usd
CY2021	OTLC	Adjustments To Additional Paid In Capital Warrant Issued Private Placement AdjustmentsToAdditionalPaidInCapitalWarrantIssuedPrivatePlacement	2190127	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	600965	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	763314	usd
CY2021	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	620052	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-10517290	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-10517290	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8158431	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8158431	usd
CY2022	us-gaap	Profit Loss ProfitLoss	4676603	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-10517290	usd
CY2022	OTLC	Gain On Sale Of Nonfinancial Asset GainOnSaleOfNonfinancialAsset	16951477	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4111079	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1975501	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1453949	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12841	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	51365	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-257810	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-27504	usd
CY2022	OTLC	Warrants Issued Connection With Private Placement WarrantsIssuedConnectionWithPrivatePlacement	2905316	usd
CY2021	OTLC	Warrants Issued Connection With Private Placement WarrantsIssuedConnectionWithPrivatePlacement	2190127	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	902141	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	763315	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	142150	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	292149	usd
CY2021	OTLC	Research Development Expenses Paid By Debt ResearchDevelopmentExpensesPaidByDebt	1500000	usd
CY2021	OTLC	Common Shares Issued Issued In Lieu Of Restricted Stock Units CommonSharesIssuedIssuedInLieuOfRestrictedStockUnits	226432	usd
CY2021	OTLC	Common Shares Issued In Lieu Of Services CommonSharesIssuedInLieuOfServices	193641	usd
CY2021	OTLC	Paycheck Protection Program Loan Forgiveness PaycheckProtectionProgramLoanForgiveness	346761	usd
CY2021	us-gaap	Depreciation Depreciation	10148	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3186	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-83091	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	873951	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	210371	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-70991	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	11792	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1452562	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4434465	usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1545052	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	158820	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	420293	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	966425	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	307500	usd
CY2021	OTLC	Repayments Of Convertible Notes Payable RepaymentsOfConvertibleNotesPayable	307500	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1815825	usd
CY2021	OTLC	Proceeds From Convertible Debt For Joint Venture ProceedsFromConvertibleDebtForJointVenture	500000	usd
CY2021	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	350050	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	100000	usd
CY2021	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	95000	usd
CY2021	OTLC	Proceeds From Payroll Protection Plan ProceedsFromPayrollProtectionPlan	92995	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1125245	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4529215	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-327317	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	94750	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	588769	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	494019	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	261452	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	588769	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	397995	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	299365	usd
CY2022	OTLC	Warrants Issued In Connection With Private Placement Debt WarrantsIssuedInConnectionWithPrivatePlacementDebt	368375	usd
CY2021	OTLC	Warrants Issued In Connection With Private Placement Debt WarrantsIssuedInConnectionWithPrivatePlacementDebt	2791092	usd
CY2022	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	570717	usd
CY2021	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	969754	usd
CY2022	us-gaap	Notes Issued1 NotesIssued1	624751	usd
CY2021	us-gaap	Notes Issued1 NotesIssued1	210301	usd
CY2022	OTLC	Contribution From Shareholder For Payment Of Liabilities ContributionFromShareholderForPaymentOfLiabilities	828258	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	193641	usd
CY2021	OTLC	Common Shares Issued In Lieu Of Restricted Stock Units CommonSharesIssuedInLieuOfRestrictedStockUnits	226432	usd
CY2021	OTLC	Paycheck Protection Program Loan Forgiven PaycheckProtectionProgramLoanForgiven	346761	usd
CY2022	OTLC	Non Cash Cost Upon Sale Of Common Stock NonCashCostUponSaleOfCommonStock	83180	usd
CY2021	OTLC	Non Cash Cost Upon Sale Of Common Stock NonCashCostUponSaleOfCommonStock	124642	usd
CY2022	OTLC	Warrants Issuance Cost WarrantsIssuanceCost	2900000	usd
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	4025000	shares
CY2022Q4	OTLC	Working Capital Deficit WorkingCapitalDeficit	16600000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2600000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1500000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zzumWxj7XLma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zpHSc442MiXh">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions and disclosure of contingent liabilities at the date of the financial statements and revenues and expense during the reporting period. Actual results could materially differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the valuation of goodwill and intangible assets for impairment, deferred tax asset and valuation allowance, and fair value of financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	-142150	usd
CY2021	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	-292149	usd
CY2022Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	198140	usd
CY2021Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	340290	usd
CY2022Q4	OTLC	Equity Securities Initial Book Value EquitySecuritiesInitialBookValue	22640519	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	22640519	usd
CY2022	OTLC	Contribution At Cost Basis ContributionAtCostBasis	5689042	usd
CY2022	OTLC	Gain On Derecognition Of Nonfinancial Asset Net Of Goodwill And Intangibles GainOnDerecognitionOfNonfinancialAssetNetOfGoodwillAndIntangibles	16951477	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni Current And Noncurrent EquitySecuritiesFvNiCurrentAndNoncurrent	22640519	usd
CY2021Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	340290	usd
CY2020Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	777024	usd
CY2021	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet	-144585	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	384075369	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2606054	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	68681	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	70549786	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	457299890	shares
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	800000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4100000	usd
CY2022	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.29	pure
CY2021	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.29	pure
CY2019Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4900000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4100000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1927749	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	775100	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1164974	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2510864	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3092723	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	332432	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	403423	usd
CY2021Q4	us-gaap	Goodwill Goodwill	21062455	usd
CY2020Q4	us-gaap	Goodwill Goodwill	21062455	usd
CY2022	OTLC	Goodwill Derecognition Upon Recording Of Gain On Nonfinancial Asset GoodwillDerecognitionUponRecordingOfGainOnNonfinancialAsset	-4880000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4111079	usd
CY2022Q4	us-gaap	Goodwill Goodwill	12071376	usd
CY2021Q4	us-gaap	Goodwill Goodwill	21062455	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1010180	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	201180	usd
CY2022Q4	OTLC	Finite Lived Intangible Assets Derecognition Upon Transfer Of Asset FiniteLivedIntangibleAssetsDerecognitionUponTransferOfAsset	-809000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1010180	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	188339	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	821841	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12841	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	51365	usd
CY2022Q4	OTLC	Finite Lived Intangible Assets Derecognition Upon Sale Of Asset FiniteLivedIntangibleAssetsDerecognitionUponSaleOfAsset	800000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1735764	usd
CY2022Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	390050	usd
CY2021Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	350050	usd
CY2021Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	9212	usd
CY2022Q4	OTLC	Debentures Notes And Other Debt DebenturesNotesAndOtherDebt	11256971	usd
CY2021Q4	OTLC	Debentures Notes And Other Debt DebenturesNotesAndOtherDebt	2384410	usd
CY2022	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	988924	usd
CY2021	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	946424	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	339687	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1250000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-500000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-1250000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	500000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	76994	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	339687	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	76994	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	150000	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	10000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	390050	usd
CY2022	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	The JVA permits GMP to seek conversion of certain convertible promissory notes entered into between the Company and GMP (see reference to Purchase Agreements and Notes below) into shares of the Common Stock of the Company within 15 business days of the execution of the JVA at a price of $0.2242 per Common Share, the closing price of the Common Share as traded on the OTCQB the day prior to the execution of the JVA, or the closing price of the Common Stock prior to the date of conversion if not within 15 business days of the JVA. Upon the execution of the JVA, Dragon will pay for and hold 55 shares of GMP Bio and the Company will pay for and hold 45 shares of GMP Bio, both to be acquired at $1.00 per share of GMP Bio. Such shares of GMP Bio were issued shortly after the date of the JVA.
CY2022Q4	OTLC	Joint Venture Valuation Amount JointVentureValuationAmount	11300000	usd
CY2022	OTLC	Licenses Agreement Descripition LicensesAgreementDescripition	The Parties also agreed that if a Rare Pediatric Disease (“RPD”) Priority Review Voucher, upon clinical approval of OT-101 Technologies for treatment of diffuse intrinsic pontine glioma (the “DIPG Voucher”), is issued to GMP Bio and GMP Bio, or a subsidiary thereof, sells the DIPG Voucher to a non-GMP subsidiary, then the Company shall be eligible to receive up to 50% of the net sales proceeds or $50 million, whichever is less. Dragon shall fund the JVA, for a total of approximately $27.7 million, based on the conditions contained in the JVA, and the Company will input the licenses under the Agreements into the JV. The Company is obligated to (i) (A) rectify the chain of legal title such that the Company is the sole legal owner of such rights, (B) complete registration as the sole owner of all the Company’s Patent Rights and (C) provide evidence of such registration that is satisfactory to Dragon; (ii) provide Dragon with copies of official documents issued by the relevant patent offices in the relevant countries evidencing the Company’s legal ownership of all the Company’s Patents Rights; and (iii) reflect the Company’s legal ownership of all the Company’s Patent Rights in the relevant online registers of the relevant patent offices in the relevant countries. The JVA intends to raise funding for the JVA through a Series A round of financing of not less than $20 million.
CY2022	OTLC	Private Placement And Financing Disclosure Textblock PrivatePlacementAndFinancingDisclosureTextblock	<p id="xdx_805_ecustom--PrivatePlacementAndFinancingDisclosureTextblock_zOfVhd9mhzy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 - <span id="xdx_821_z39IGDc8m0M7">PRIVATE PLACEMENT AND JH DARBIE FINANCING</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the period from July 2020 to March 2021, the Company entered into subscription agreements with certain accredited investors pursuant to the JH Darbie Financing, whereby the Company issued and sold a total of <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20200701__20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zRQjn380USJh" title="Sale of transaction shares">100</span> Units, for total gross proceeds of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20200701__20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_z1rb3tMTW4S8" title="Proceeds from private placement">5</span> million, pursuant to the JH Darbie Placement Agreement, with each Unit consisting of:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">■</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember_z8WwhQNhVYl2" title="Number of common stock issued">25,000</span> shares of Edgepoint Common Stock for a price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember_z6Pxr1q5Ndmf" title="Shares issued price per share">1.00</span> per share of Edgepoint Common Stock.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">■</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">One convertible promissory note, convertible into up to <span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20200701__20210331__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember_zPbTGJ9a7j9g" title="Number of convertible promissory note converted shares">25,000</span> shares of Edgepoint Common Stock, at a conversion price of $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210331__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember_zNnBynBghxWf" title="Conversion price">1.00</span> per share or up to <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20200701__20210331__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--RangeAxis__srt--MaximumMember_zOOhLuzboULb" title="Number of convertible promissory note converted shares">138,889</span> shares of the Company’s Common Stock, at a conversion price of $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210331__us-gaap--DebtInstrumentAxis__custom--OneConvertiblePromissoryNoteMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--RangeAxis__srt--MaximumMember_zCqikQ8lvQk7" title="Conversion price">0.18</span> per share.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">■</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_zAivBZoOeOPf" title="Warrants to purchase common stock">50,000</span> warrants to purchase an equivalent number of shares of Edgepoint Common Stock at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_zohobby8T9I9" title="Warrants exercise price">1.00</span> per share or an equivalent number of shares of the Company’s Common Stock at $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_zLcpk80JUJz8" title="Shares issued price per share">0.20</span> per share with a <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_z3zCsQcqQrWi" title="Warrant term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl1483">three</span></span>-year expiration date.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p id="xdx_894_ecustom--ScheduleOfFundsReceivedUnderTheSubscriptionAgreementFromThePrivatePlacementNetOfDebtDiscount_ztrXdXDkZ5S7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, and 2021, debt recorded under the JH Darbie Financing, net of debt discounts, consist of the following amounts:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zE47MNXU1Jh7" style="display: none">SCHEDULE OF FUNDS RECEIVED UNDER THE SUBSCRIPTION AGREEMENT</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_z0jHyj7p65V5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20211231_zK80ErOr2bUa" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zTxU4nxcMrs9" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Subscription agreements - accredited investors</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,342,064</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,353,253</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__custom--RelatedPartyMember_zypkhTmYe8v4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Subscription agreements – related party</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">125,547</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">109,046</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z72jbXytPFLf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total convertible promissory notes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,466,611</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,462,299</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z5wmkTrDMvh8" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible promissory notes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,466,611</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,462,299</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zH6LmzzdLaK2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred approximately $<span id="xdx_906_eus-gaap--DeferredFinanceCostsNet_iI_pn4n6_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwd7QlFVOKS8" title="Issuance cost">0.64</span> million of issuance costs, including legal costs of approximately $<span id="xdx_90B_eus-gaap--LegalFees_pp0p0_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQPo7BZGUl01" title="Legal costs">39,000</span>, that are incremental costs directly related to the issuance of the various instruments bundled in the offering. As of the date of this Report, the PPM notes are in default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently with the sale of the Units, JH Darbie was granted, for nominal consideration, a warrant, exercisable over a five-year period, to purchase <span id="xdx_90E_ecustom--PercentageOfUnitsGranted_dp_uPure_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_zqJ4QM84vIW9" title="Percentage of units granted">10</span>% of the number of Units sold in the JH Darbie Financing. As such, the Company granted <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_zIXN6vb6YT8l" title="Issued in transaction">10</span> Units to JH Darbie pursuant to the JH Darbie Placement Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The terms of convertible notes are summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">■</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term: Through March 31, 2023.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">■</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coupon: <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20200701__20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember_zKhVS1UkTq86" title="Interest rate">16</span>%.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">■</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible at the option of the holder at any time in the Company’s Common Stock or Edgepoint Common Stock.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">■</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The conversion price is initially set at $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210331__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__srt--RangeAxis__srt--MaximumMember_zfxra517cDs5" title="Conversion price">0.18</span> per share for the Company’s Common Stock or $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20210331__us-gaap--TypeOfArrangementAxis__custom--JHDarbiePlacementAgreementMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember_zWHG1RhbvHn5" title="Conversion price">1.00</span> for Edgepoint Common Stock, subject to adjustment.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company allocated the proceeds among the freestanding financial instruments that were issued in the single transaction using the relative fair value method, which affects the determination of each financial instrument’s initial carrying amount. The Company utilized the relative fair value method as none of the freestanding financial instruments issued as part of the single transaction are measured at fair value. Under the relative fair value method, the Company made separate estimates of the fair value of each freestanding financial instrument and then allocated the proceeds in proportion to those fair value amounts. The Company recorded aggregate non-controlling interests of approximately $<span id="xdx_90B_eus-gaap--MinorityInterestPeriodIncreaseDecrease_pn6n6_c20200101__20201231__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zI9EgTGdCJbf" title="Non controlling interest">1</span> million in Edgepoint. Non-controlling interests represent the portion of net assets in consolidated entities that are not owned by the Company and are reported as a component of equity in the consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the multiple closings of the Company, during the six months ended June 30, 2021, under the private placement memorandum with JH Darbie, the estimated volume weighted grant date fair value of approximately $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--JHDarbieAndCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJDjqSaQ531" title="Estimated volume weighted grant date fair value">0.21</span> per share associated with the warrants to purchase up to <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--JHDarbieAndCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zklaMRTQ6585" title="Warrants to purchase">2,035,000</span> shares of common stock issued in this offering, or a total of approximately $<span id="xdx_902_eus-gaap--AdditionalPaidInCapital_iI_pn5n6_c20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--JHDarbieAndCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_za4pIqkER002" title="Additional paid in capital">0.7</span> million, was recorded to additional paid-in capital on a relative fair value basis. All warrants sold in this offering had an exercise price of $<span id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--JHDarbieAndCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXhwDhaRXgd7">0.20</span> per share of the Company stock or $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20210630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--EdgepointAIIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpfIu9lURKg8" title="Share price">1.00</span> per share of Edge Point, subject to adjustment, are exercisable immediately and expire <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_pid_dc_c20210630__dei--LegalEntityAxis__custom--JHDarbieAndCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztHeNdmvVKJ9" title="Warrant term">three years</span> from the date of issuance. The fair value of the warrants was estimated using a Black Scholes valuation models using the following input values:</span></p> <p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_gL3FVAALMORAN-WR_zdik01r5CNz9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_z5x0nt2TcZR7" style="display: none">SCHEDULE OF FAIR VALUE WARRANTS ESTIMATED USING BLACK SCHOLES VALUATION MODEL</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected Term</td><td> </td> <td colspan="2" style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zxs7BkEqegZ9" title="Expected Term">1.5</span> years</td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zln4Wlu4RTZ2" title="Fair value of warrant measurement percentage">152.3</span>%-<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zPKIRRIwgDvc" title="Fair value of warrant measurement percentage">164.8</span></span></td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free interest rates</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zghlgQtXN2R8" title="Fair value of warrant measurement percentage">0.09</span>%-<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zuqf0f1EvO2b" title="Fair value of warrant measurement percentage">0.11</span></span></td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: justify">Dividend yields</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z7ZrULrZxBF" title="Fair value of warrant measurement percentage">0.00</span></td><td style="width: 1%; text-align: left">%</td> </tr> </table> <p id="xdx_8A3_z3WQht1J5B8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, the Company and all except one of the Investors agreed to extend the maturity date of the Notes from March 31, 2022, to March 31, 2023. In consideration for the extension of the Notes, the Company issued to the Investors an aggregate of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220228__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zvlIa3EBRdc5" title="Number of warrant issued">33,000,066</span> Oncotelic Warrants at a price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220228__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zgFwQrBHVgMd" title="Warrants exercise price">0.15</span> per share of Company’s Common Stock. Each Investor will be entitled to receive <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220228__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zgKwj2uZ674f" title="Number of warrants for each warrant purchased">333,334</span> Oncotelic Warrants for each Unit purchased. Upon the amendment of the terms of the convertible notes under the private placement memorandum. As incentive to extend the maturity date, approximately 33 million warrants were issued to the Unit Holders who participated in the amendment, The Company repaid the 1-unit holder who did not participate in the amendment shortly after March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviewed the guidance per ASC 470-60 Troubled debt restructurings and ASC 470-50 Debt-Modifications and Extinguishments and concluded that the terms of the agreements were substantially different as of September 30, 2022, and, accounted for the transaction as a debt extinguishment. The loss is recognized equal to the difference between the net carrying amount of the original debt and the fair value of the modified debt instrument.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At March 31, 2022, the Company estimated the fair value of the warrants issued in conjunction with the amendment of the private placement under the JH Darbie financing based on assumptions used in the Black-Scholes valuation model. The key valuation assumptions used consists, in part, of the price of the Company’s Common Stock, a risk-free interest rate based on the yield of a Treasury note and expected volatility of the Company’s Common Stock all as of the measurement date. The Company used the following assumptions to estimate fair value of the warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_C09_gL3FVAALMORAN-WR_zdugva2WNI3g"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <div id="xdx_C04_gL3FVAALMORAN-WR_zZm23TUVFdPd"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_301_134_zHLG14NJG827" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SCHEDULE OF FAIR VALUE WARRANTS ESTIMATED USING BLACK SCHOLES VALUATION MODEL (Details)"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Strike price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20220331_zo2GcRGNMA1e" title="Strike price">0.15</span></td><td style="width: 2%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zlIcNSvpGGrf" title="Expected Term">1</span> year </span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zIoTjg6qaP4" title="Fair value of warrant measurement percentage">115.1</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rates</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_znWaMuPSzAfb" title="Fair value of warrant measurement percentage">1.36</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Dividend yields</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zcqomDe3VO21" title="Fair value of warrant measurement percentage">0.00</span></td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_C01_gL3FVAALMORAN-WR_zIkMZgMq30Fe"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All the warrants issued in conjunction with the amendment #5 had an exercise price of $<span id="xdx_904_eus-gaap--SharePrice_iI_pid_c20221231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zggHtewQ8pRi" title="Share price">0.15</span> per share and are immediately exercisable and expire two years from the date of issuance or February 9, 2024. The warrants resulted in an aggregate fair value of approximately $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20220101__20221231__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zzfkvoxuJuAe" title="Fair value adjustment of warrants">2.9</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized amortization expense related to the debt discount and debt issuance costs of $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember_zM99rUEx9tUe" title="Amortization of debt discount and debt issuance costs">90,737</span> and $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--InterestExpenseMember_zK0WOWnrt4Ak" title="Amortization of debt discount and debt issuance costs">1,229,865</span> for the fiscal years ended December 31, 2022, and 2021 respectively, which is included in interest expense in the statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	OTLC	Schedule Of Funds Received Under The Subscription Agreement From The Private Placement Net Of Debt Discount ScheduleOfFundsReceivedUnderTheSubscriptionAgreementFromThePrivatePlacementNetOfDebtDiscount	<p id="xdx_894_ecustom--ScheduleOfFundsReceivedUnderTheSubscriptionAgreementFromThePrivatePlacementNetOfDebtDiscount_ztrXdXDkZ5S7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, and 2021, debt recorded under the JH Darbie Financing, net of debt discounts, consist of the following amounts:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zE47MNXU1Jh7" style="display: none">SCHEDULE OF FUNDS RECEIVED UNDER THE SUBSCRIPTION AGREEMENT</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20221231_z0jHyj7p65V5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20211231_zK80ErOr2bUa" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-weight: bold; text-align: left">Convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zTxU4nxcMrs9" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Subscription agreements - accredited investors</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,342,064</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,353,253</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__srt--TitleOfIndividualAxis__custom--RelatedPartyMember_zypkhTmYe8v4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Subscription agreements – related party</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">125,547</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">109,046</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z72jbXytPFLf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total convertible promissory notes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,466,611</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,462,299</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ConvertibleDebt_iI_hus-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z5wmkTrDMvh8" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Convertible promissory notes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,466,611</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,462,299</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q1	us-gaap	Share Price SharePrice	0.15
CY2021	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	3435000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16592620	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.30
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	2359	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	11.88
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	9100000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.10
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	25690261	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	25690261	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.23
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.23
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	7280000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3941301	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.78
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	12652761	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.15
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1442	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	19.80
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16592620	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.30
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	25690261	shares
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P8Y
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.30
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	15497761	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.05
CY2022	OTLC	Unamortized Share Based Compensation UnamortizedShareBasedCompensation	0	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	7280000	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	900000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	900000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	900000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	900000	usd
CY2020Q4	OTLC	Class Of Warrant Or Right Reissuance ClassOfWarrantOrRightReissuance	13750000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	53314424	shares
CY2021Q4	OTLC	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.20
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	38623816	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	10865385	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	81072855	shares
CY2022Q4	OTLC	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.18
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	18702500	shares
CY2020Q4	OTLC	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.20
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	34611924	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	53314424	shares
CY2021Q4	OTLC	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	0.20
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	81072855	shares
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y11M1D
CY2022Q4	OTLC	Class Of Warrant Weighted Average Exercise Price Of Warrants ClassOfWarrantWeightedAverageExercisePriceOfWarrants	0.18
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	81072855	shares
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2575000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1164000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2752000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5736000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	323000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	361000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1372000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4792000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	528000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	528000	usd
CY2022Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	2146000	usd
CY2021Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	2246000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	53456000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	57343000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	58860000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	67678000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58860000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67678000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	58900000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	67700000	usd
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	Portions of these carryforwards will expire through 2038

Files In Submission

Name	View Source	Status
0001493152-23-012352-index-headers.html	Edgar Link	pending
0001493152-23-012352-index.html	Edgar Link	pending
0001493152-23-012352.txt	Edgar Link	pending
0001493152-23-012352-xbrl.zip	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
otlc-20221231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
otlc-20221231_lab.xml	Edgar Link	unprocessable
otlc-20221231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
otlc-20221231_cal.xml	Edgar Link	unprocessable
otlc-20221231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OTLC
Oncotelic Therapeutics, Inc. Stock $otlc

2023 Q2 Form 10-K Financial Statement

#000149315223012352 Filed on April 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OTLC Oncotelic Therapeutics, Inc. Stock $otlc

2023 Q2 Form 10-K Financial Statement

#000149315223012352 Filed on April 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OTLC
Oncotelic Therapeutics, Inc. Stock $otlc